IP Library Granted Patent US 11,234,454
Granted Patent B2
US 11,234,454 · App. 15/839,370 · Granted Feb 1, 2022

Compositions and methods that modulate cholesterol in a companion animal

Inventors: Rondo P Middleton (Creve Coeur, MO); Brian M Zanghi (Ballwin, MO); Serge Andre Dominique Rezzi (Semsales, CH); Steven S Hannah (Chesterfield, MO)
Assignee: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
A23K50/40A23K10/00A23K20/142A23K20/147A23K20/158A23K20/163A23K20/26A23K40/00A61K31/16A61K31/19A61K31/191A61K31/194A61K31/20A61K31/202A61K31/355A61K31/575A61K31/661A61K31/708A61K31/7068A61P3/06A61P9/00A61P9/10A61P29/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,234,454
App. No.
15/839,370
Granted
Feb 1, 2022
Kind
B2
Abstract

Cholesterol, high-density lipoproteins, and low-density lipoproteins in a companion animal can be improved by adjusting the diet of the animal to increase the amount of a compound which positively or negatively modulates the cholesterol, high-density lipoproteins, or low-density lipoproteins or adjusting the diet of the animal to decrease the amount of a compound which positively or negatively modulates cholesterol, high-density lipoproteins, or low-density lipoproteins.

Claims (15)

1. A pet food composition, comprising:

protein, carbohydrates, fat, fiber, and

at least 6 distinct metabolites including 2 distinct metabolites for modulating each one of cholesterol, high-density lipoproteins, and low-density lipoproteins in a companion animal;

wherein the metabolite that modulates cholesterol is selected from the group consisting of palmitoyl sphingomyelin, X-13215, 1-stearoylglycerol (1-monostearin), alpha-tocopherol, 7-alpha-hydroxycholesterol, 1-palmitoylglycerol (1-monopalmitin), 7-beta-hydroxycholesterol, X-17010, glycerophosphorylcholine (GPC), X-16120, 2-linoleoylglycerophosphoethanolamine, 5-methyl-2′-deoxycytidine, caproate (6:0), 1-linoleoylglycerophosphoethanolamine, glycerol 3-phosphate (G3P), 2-arachidonoylglycerophosphoethanolamine, glycerol 2-phosphate, dihydrocholesterol, pelargonate (9:0), stearamide, 2-palmitoylglycerophosphoethanolamine, malate, heptanoate (7:0), and mixtures thereof;

wherein the metabolite that modulates high-density lipoproteins is selected from the group consisting of palmitoyl sphingomyelin, X-13215, alpha-tocopherol, 1-stearoylglycerol (1-monostearin), 7-alpha-hydroxycholesterol, X-17010, 1-arachidonoylglycerophosphocholine, 2-docosapentaenoylglycerophosphocholine, 7-beta-hydroxycholesterol, 1-palmitoylglycerol (1-monopalmitin), 1-docosapentaenoylglycerophosphocholine, caproate (6:0), arachidonate (20:4n6), X-17612, 3-hydroxybutyrate (BHBA), 2-arachidonoylglycerophosphocholine, pelargonate (9:0), stearamide, N2,N2-dimethylguanosine, 1-linoleoylglycerophosphocholine, dihydrocholesterol, X-11412, 1-stearoylglycerophosphocholine, X-17147, glycerate, heptanoate (7:0), 1-docosahexaenoylglycerophosphocholine, dihomo-linoleate (20:2n6), 2-linoleoylglycerophosphocholine, 2-palmitoylglycerophosphocholine, and mixtures thereof;

wherein the metabolite that modulates low-density lipoproteins is selected from the group consisting of 1-stearoylglycerol (1-monostearin), X-13215, palmitoyl sphingomyelin, alpha-tocopherol, 7-alpha-hydroxycholesterol, 2-linoleoylglycerophosphoethanolamine, glycerophosphorylcholine (GPC), 7-beta-hydroxycholesterol, 1-linoleoylglycerophosphoethanolamine, X-17010, 2-palmitoylglycerophosphoethanolamine, 1-palmitoylglycerol (1-monopalmitin), caproate (6:0), 5-methyl-2′-deoxycytidine, 2-arachidonoylglycerophosphoethanolamine, malate, glycerol 2-phosphate, glycerol 3-phosphate (G3P), 2-oleoylglycerophosphoethanolamine, N2,N2-dimethylguanosine, and mixtures thereof; and

wherein the at least 6 distinct metabolites are present in amounts that are at least one of (i) from about 0.01 weight % to about 10 weight % of the pet food food composition or (ii) from about 1 IU to about 500,000 IU per kilogram of the pet food composition,

wherein the pet food composition provides at least a 5% increase or at least a 5% decrease in the amount of at least one of cholesterol, high-density lipoproteins, or low-density lipoproteins in the companion animal upon administration of the pet food to the companion animal.

2. The pet food composition of claim 1 , wherein the composition comprises at least 9 distinct metabolites, including at least 3 distinct metabolites for modulating each one of cholesterol, high-density lipoproteins, and low-density lipoproteins in a companion animal.

3. The pet food composition of claim 1 , wherein the composition comprises at least 12 distinct metabolites, including at least 4 distinct metabolites for modulating each one of cholesterol, high-density lipoproteins, and low-density lipoproteins in a companion animal.

4. The pet food composition of claim 1 , wherein the metabolite that modulates cholesterol is selected from the group consisting of palmitoyl sphingomyelin, X-13215, 1-stearoylglycerol (1-monostearin), alpha-tocopherol, 7-alpha-hydroxycholesterol, 1-palmitoylglycerol (1-monopalmitin), 7-beta-hydroxycholesterol, X-17010, glycerophosphorylcholine (GPC), X-16120, 2-linoleoylglycerophosphoethanolamine, 5-methyl-2′-deoxycytidine, caproate (6:0), and mixtures thereof.

5. The pet food composition of claim 1 , wherein the metabolite that modulates high-density lipoprotein is selected from the group consisting of palmitoyl sphingomyelin, X-13215, alpha-tocopherol, 1-stearoylglycerol (1-monostearin), 7-alpha-hydroxycholesterol, X-17010, 1-arachidonoylglycerophosphocholine, 2-docosapentaenoylglycerophosphocholine, 7-beta-hydroxycholesterol, 1-palmitoylglycerol (1-monopalmitin), 1-docosapentaenoylglycerophosphocholine, caproate (6:0), arachidonate (20:4n6), and mixtures thereof.

6. The pet food composition of claim 1 , wherein the metabolite that modulates low-density lipoprotein is selected from the group consisting of 1-stearoylglycerol (1-monostearin), X-13215, palmitoyl sphingomyelin, alpha-tocopherol, 7-alpha-hydroxycholesterol, 2-linoleoylglycerophosphoethanolamine, glycerophosphorylcholine (GPC), 7-beta-hydroxycholesterol, 1-linoleoylglycerophosphoethanolamine, X-17010, 2-palmitoylglycerophosphoethanolamine, 1-palmitoylglycerol (1-monopalmitin), and mixtures thereof.

7. The pet food composition of claim 1 , wherein the pet food composition provides at least a 10% increase in the amount of high-density lipoprotein in the companion animal.

8. The pet food composition of claim 1 , wherein the pet food composition provides at least a 10% decrease in the amount of at least one of cholesterol and low-density lipoprotein in the companion animal.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0001 →
CORRECTIVE ASSIGNMENT TO CORRECT THE PATENT NUMBER 16062921 PREVIOUSLY RECORDED ON REEL 049391 FRAME 0756. ASSIGNOR(S) HEREBY CONFIRMS THE PATENT NUMBER SHOULD HAVE BEEN 16062912. Recorded Jul 3, 2020
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 054082/0165 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ENGLISH TRANSLATION TO SHOW THE FULL AND CORRECT NEW NAME IN SECTION 51. PREVIOUSLY RECORDED AT REEL: 049391 FRAME: 0756. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER. Recorded Jun 13, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049853/0398 →
MERGER Recorded Jun 6, 2019
From: NESTEC S.A.
To: SOCIÉTÉ DES PRODUITS NESTLÉ S.A.
Reel/Frame 049391/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2018
From: MIDDLETON, RONDO P; ZANGHI, BRIAN M; REZZI, SERGE ANDRE DOMINIQUE; HANNAH, STEVEN S
To: NESTEC SA
Reel/Frame 044843/0862 →